Form 4: Vor Biopharma Inc. Executive Eyal C. Attar Reports Stock Transaction
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports the disposal of 1,146 shares of common stock to cover tax obligations related to restricted stock units.
Summary
- On November 1, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., disposed of 1,146 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The shares were disposed of at a price of $0.8.
- Following the transaction, Attar directly owns 92,772 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates a standard tax-related stock disposal.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of stock transaction: disposal of 1,146 shares. |
| 11/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.